Bharat Stories
Light of Knowledge

Zydus Needle Free Corona Vaccine Zycov D

0 370

According to : zydus needle free corona vaccine zycov d is the world’s first DNA-based jab against COVID-19 and should be given intradermally three times, at days 0, 28, and 56 using PharmaJet needle-free applicator.

Phase 3 clinical trial results demonstrated 66.6 percent efficacy against COVID-19 infections among vaccinated subjects; no severe or moderate cases occurred among this population.

Stability and sterility

Zydus needle-free corona vaccine ZYCOV D ( : zydus needle free corona vaccine zycov d)  is the world’s first DNA-based coronavirus (SARS-CoV-2) vaccine developed in India and approved for emergency use by the Drugs Controller General of India. Phase 3 clinical trials at various locations around India are currently ongoing for this groundbreaking product.

This vaccine utilizes plasmid DNA, a type of genetic material found in bacteria which transmits instructions directly to cells. This form of the vaccine is more stable than its mRNA counterpart and can be stored at higher temperatures allowing easier transport.

Plasmid DNA vaccines offer an alternative to vector-based immunity, such as insufficient responses to target antigens after vaccination, as well as protecting against mutations that result in new strains or variants of a virus.

It allows the vaccine to be more efficient and effective at combatting COVID-19, particularly for protecting vulnerable populations such as infants, pregnant women, and elderly people. Furthermore, this reduced likelihood of adverse side effects such as inflammation or rash.

Plasmid DNA vaccines offer several distinct advantages over their non-viral counterparts, including being easy to produce with limited biosafety requirements and thus cutting both cost and time for development and production.

Additionally, it can easily be scaled up to larger volumes, enabling it to be produced and distributed globally – an invaluable feature when manufacturing vaccines that must be distributed widely or to areas without access to refrigeration facilities.

Plasmid DNA vaccines can be stored easily at high temperatures, making them perfect for global transportation without cold chain breakdown issues that lead to the wastage of supplies. Furthermore, they’re more durable than mRNA vaccines which require transcription and protein production for an immune response.

This vaccine is administered via intradermal vaccination over 28-56 days using the PharmaJet system which uses high-pressured liquid to administer injections without needles. According to its creators, frontline workers and field vaccinators may use this device.


At present, at least ten DNA-based COVID-19 vaccines are in clinical development; among these is Zydus Cadila’s needle-free corona vaccine zycov d. Other candidates for development are lipid nanoparticles, electroporation, jet injectors and gene guns with various degrees of success and immune responses that vary among technologies used.

Plasmid DNA offers another promising platform, as its rapid generation allows for new constructs to be quickly created. This could enable next-generation DNA vaccines that address mutations of viruses.

One such recombinant vaccine from Pennsylvania-based INOVIO is currently undergoing Phase 3 trials and could become available for widespread use in future vaccines.

Pharmajet Tropis is a needle-free system designed to administer the plasmid DNA vaccine intradermally via an outward pressurized jet of fluid that penetrates skin punctures to deliver it directly into the bloodstream.

According to Pharmajet Tropis’ company website, this delivery method meets World Health Organization criteria for Performance Quality and Safety evaluation, while remaining cost-effective as an affordable solution.

The company asserts that its needle-free approach can significantly lower the risk of adverse events compared to conventional injection methods, with only four percent of vaccine-eligible participants experiencing injection site pain and localized itching while only a handful experienced additional side effects such as redness or soreness in certain instances.

Plasmid DNA vaccines boast excellent immunogenicity and have low dose requirements to generate an immune response, making it more cost-effective than other DNA-based vaccines that often require two doses of one protein vaccine to produce full immunity.

At our single-center, open-label, non-randomized Phase 1 trial in India, injecting small doses (0.1 microgram) of COVID-19 vaccine using the Pharmajet Tropis device was safe and resulted in strong antibody responses without producing severe or moderate reactions or leading to any serious health problems.

Phase I trial of plasmid DNA-based vaccine administered intradermally as either one dose or in two dosage regimens by intradermal injection at Cadila Healthcare Limited clinical unit of Zydus Research center located in Ahmedabad, India.


Zydus Cadila of India developed the needle-free corona vaccine Zycov d, a DNA-based vaccine. This vaccine contains plasmid DNA which is transformed into messenger RNA (mRNA), then translated into the spike protein of SARS-CoV-2 virus.

Phase 1 trials showed no severe adverse events or deaths among adults who received the vaccine. According to the company, tolerance levels among approximately 1000 adolescents who participated in phase 3 trials were also similar.

The company reported that the vaccine-induced balanced humoral and cellular immune responses after three doses, with participants showing both antibodies and T cells after each vaccination dose.

In comparison to participants receiving 2 mg intravenously doses, those given only 1 mg doses at once intradermally showed significantly lower humoral immune responses.

Once it receives all necessary approvals, the company plans to initiate a Phase III trial with approximately 30,000 volunteers in various settings – community centers, hospitals, veterinarian clinics and veterinary practices among them – which will give an in-depth analysis of ZyCoV-D’s safety and immunogenicity.


Zydus Cadila, an Indian pharmaceutical firm, announced they have received approval from the Drugs Controller General of India (DCGI) to administer their needle-free corona vaccine zycov d under emergency use authorization.

Developed locally against COVID-19 and with approval granted for emergency use authorization in adults and adolescents aged 12 years and above, Ahmedabad-based Zydus Cadila confirmed.

Zydus VTEC operates its state-of-the-art facility in Gujarat to produce vaccines. Manufacturing processes and material transfers within the facility are fully automated to keep costs to a minimum and achieve efficient operations.

Clinical trials performed on this vaccine against SARS-CoV-2 proved that it is 66.6 percent effective against cases with positive RT-PCR tests, according to its manufacturer. As a result, Central Government officials have now begun receiving supplies of this vaccine from them.

Zydus will begin administering its vaccine at its government vaccination centers and all authorized centres across states and union territories, in addition to providing it for private sector customers, in an upcoming phase.

According to the company, their vaccine will be available for administration by trained vaccinators using a PharmaJet injector that delivers the vaccine through skin contact instead of needing needles and syringes.

This technology reduces needlestick injuries while simultaneously alleviating side effects like nausea, fatigue and pain, according to them.

Marking an important step forward for vaccine technology, Zydus’ needle-free corona vaccine zycov-d is the first needle-free DNA-based corona vaccine approved by any regulator.

The plasmid DNA platform provides an adaptable platform that makes vaccines easily adaptable to new virus mutations. Furthermore, its lower cold chain requirements mean it can be stored longer in remote locations.

DNA-based vaccines offer another advantage by being suitable for people of various immune systems compared to traditional inactivated vaccines which must only be given once. According to the company, this makes DNA vaccines an excellent way of providing protection from multiple diseases at once.

Zydus needle-free corona zycov-d was initially tested against SARS-CoV-2 coronavirus in clinical trials and found to be 66.6 percent effective against cases diagnosed with an RT-PCR positivity test. Since then, Zydus announced they have started providing this vaccine to the Central Government.

Keep reading to get more information on : zydus needle free corona vaccine zycov d

Leave A Reply

Your email address will not be published.